Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2- fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method

Pharmaceutical Research

Volumn 16, Issue 8, 1999, Pages 1226-1232

  Chen, Chun Lin ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

HI 240; HPLC; Nonnucleoside inhibitor; Pharmacokinetics

Indexed keywords

N [2 (2 FLUOROPHENETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; EVALUATION STUDIES; FEMALE; HIV-1 REVERSE TRANSCRIPTASE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAPERITONEAL; MICE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; THIOUREA; TISSUE DISTRIBUTION;

EID: 0032816084     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014814313681     Document Type: Article

References (13)

1. 1. S. D. Young. Non-nucleoside inhibitors of HIV-1 reverse transcriptase. Perspectives in Drug Discovery Design 1:181-192, 1993.
2. 2. E. De Clercq. The role of non-nucleoside reverse transcriptase inhibitors (NNRIs) in the therapy of HIV-1 infection. Antiviral Res. 38:153-179, 1998.
3. 3. R. Vig, C. Mao, T. K. Venkatachalam, L. T. Ahlgren, E. A. Sudbeck, and F. M. Uckun. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Bioorg. Med. Chem. 6:1789-1797 (1998).
4. 4. C. Mao, E. A. Sudbeck, T. K. Venkatachalam, and F. M. Uckun. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-dibromopyridyl)-thiourea] (H1-236) as a potent nonnucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg. Med. Chem. Lett. 9:1593-1598 (1999).
5. 5. C. Mao, R. Vig, T. K. Venkatachalam, E. Sudbeck, and F. M. Uckun. Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2[(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 8(I):2213-2218 (1998).
6. 6. C. L. Chen, R. Malaviya, C. Navara, H. Chen, B. Bechard, G. Mitcheltree, X. P. Liu, and F. M. Uckun. Pharmacokinetics and biological activity of the novel mast cell inhibitor, 4-(3′-hydroxy-phenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm. Res. 16:117-122 (1999).
7. 7. C. L. Chen, H. Chen, D. M. Zhu, and F. M. Uckun. Quantitative high-performance liquid chromatography based detection method for calphostin C, a naturally occurring perylenequinone with potent antileukemic activity. J. Chromatogr. B. 724:157-162 (1999).
8. 8. H. Rosenkrantz, Z. Hadidian, H. Seay, and M. M. Masson. Dimethyl sulfoxide: its stroid solubility and endocrinologic and pharmacologic-toxicologic characteristics. Cancer Chemother. Rep. 31:7-24 (1963).
9. 9. J. E. Wilson, D. E. Brown, and E. K. Timmens. A toxicological study of dimethyl sulfoxide. Toxicol. Appl. Pharmacol. 7:104-112 (1965).
10. 10. M. Gibaldi and D. Perrier. Pharmacokinetics. Marcel Dekker, Inc., New York and Basel, 1982. 13.
11. 11. B. Davies and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
12. 12. C. Ahgren, K. Backro, F. W. Bell, A. S. Cantrell, M. Clemens, J. M. Colacino, J. B, Deeter, J. A. Engelhardt, M. Hogberg, S. R. Jaskunas, N. G. Johansson, C. L. Jordan, J. S. Kasher, M. D. Kinnick, P. Lind, C. Lopez, J. M. Jr. Morin, M. A. Muesing, R. Noreen, B. Oberg, C, J. Paget, J. A. Palkowitz, C. A. Parrish, P. Pranc, M. K. Rippy, C. Rydergard, C. Sahlberg, S. Swanson, R. J. Ternansky, T. Unge, R. T. Vasileff, L. Vrang, S. J. West, H. Zhang, and X. X. Zhou. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type I reverse transcriptase. Antimicrob. Agents Chemother. 39:1329-1335 (1995).
13. 13. P. de Miranda, T. C. Burnette, and S.S. Good. Tissue distribution amd metabolic disposition of zidovudine in rats. Drug Metab. Dispos. 18:315-320 (1990).